868 results on '"Rouprêt M"'
Search Results
2. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
3. Photodynamic cystoscopy for bladder cancer diagnosis and for NMIBC follow-up: An overview of systematic reviews and meta-analyses
4. Ureteropelvic junction obstruction and renal calculi: Simultaneous treatment by robot-assisted laparoscopic pyeloplasty and transcutaneous retrograde flexible ureteroscopy. Technique description and early outcomes
5. Biochemical relapse predictive factors in patients with lymph node metastases during radical prostatectomy
6. French AFU Cancer Committee Guidelines - Update 2022-2024: testicular germ cell cancer
7. French AFU Cancer Committee Guidelines - Update 2022-2024: penile cancer
8. French AFU Cancer Committee Guidelines Update 2022–2024: Adrenal tumor – Assessment of an adrenal incidetaloma and oncological management
9. French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease
10. French AFU Cancer Committee Guidelines – Update 2022–2024: Upper urinary tract urothelial cancer (UTUC)
11. French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC)
12. French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance
13. French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer
14. French AFU Cancer Committee Guidelines – Update 2022–2024: Muscle-Invasive Bladder Cancer (MIBC)
15. Comparison of open and robotic-assisted partial nephrectomy approaches using multicentric data (UroCCR-47 study)
16. Multicenter external validation of the radical cystectomy pentafecta in a European cohort of patients undergoing robot-assisted radical cystectomy with intracorporeal urinary diversion for bladder cancer
17. Positive environmental impact of remote teleconsultation in urology during the COVID-19 pandemic in a highly populated area
18. COVID19 pandemic impacts on anxiety of French urologist in training: Outcomes from a national survey
19. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
20. Elastic fusion biopsy versus systematic biopsy for prostate cancer detection: Results of a multicentric study on 1119 patients
21. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?
22. Narrative review of PET/CT performances at biochemical recurrence in prostate cancer after radical prostatectomy and impact on patient disease management: Revue narrative à propos des performances de la TEP/TDM en cas de récidive biochimique après prostatectomie radicale dans le cancer de la prostate et impact sur la prise en charge des patients
23. Transition zone and anterior stromal prostate cancers: Evaluation of discriminant location criteria using multiparametric fusion-guided biopsy
24. Spanish adaptation of the recommendations for the appropriate use of social media in urology of the European Association of Urology
25. Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study
26. Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract
27. Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: A meta-analysis and a systematic review of current evidence from comparative studies
28. Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma
29. 2001P Epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial cancer in France: A non-interventional database study
30. The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy
31. O3 - Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum
32. Robot-assisted laparoscopic nephron sparing surgery for tumors over 4 cm: Operative results and preliminary oncologic outcomes from a multicentre French study
33. Reporting and grading of complications after urologic surgical procedures: An ad hoc EAU guidelines panel assessment and recommendations
34. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update
35. Tumours of the bladder: What does the urologist expect from imaging?
36. Erectile dysfunction and diabetes: A review of the current evidence-based medicine and a synthesis of the main available therapies
37. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update
38. Oncological outcomes in patients undergoing radical nephrectomy and vena cava thrombectomy for renal cell carcinoma with venous extension: A single-centre experience
39. Workload and surgical training of residents in France: Results of a national inquiry
40. Is there a volume–outcome relationship for partial nephrectomy?
41. LBA102 THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment
42. Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy
43. Apport potentiel de l’assistance robotisée dans le traitement chirurgical du cancer de prostate localisé
44. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial
45. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)
46. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees
47. Predictive factors of chronic kidney disease stage V after partial nephrectomy in a solitary kidney: a multi-institutional study
48. P119 - Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, non-invasive bladder tumors in 2019?
49. Bacillus Calmette-Guerin infection following intravesical instillation: Does the strain matter?
50. EE171 Hospital Costs of Muscle-Invasive Urothelial Carcinoma (MIUC) Patients Undergoing Radical Surgery: A French Real-World Retrospective Study Based on the National Hospitalization Database (PMSI)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.